These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 8988729

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR, Hanlon AL, Patchefsky A, Al-Saleem T, Hanks GE.
    Int J Radiat Oncol Biol Phys; 1998 Jul 15; 41(5):1087-92. PubMed ID: 9719119
    [Abstract] [Full Text] [Related]

  • 3. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE.
    Int J Radiat Oncol Biol Phys; 2002 Mar 15; 52(4):888-92. PubMed ID: 11958880
    [Abstract] [Full Text] [Related]

  • 4. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.
    Pinover WH, Hanlon AL, Horwitz EM, Hanks GE.
    Int J Radiat Oncol Biol Phys; 2000 Jun 01; 47(3):649-54. PubMed ID: 10837947
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.
    Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE.
    Cancer; 2001 Sep 01; 92(5):1281-7. PubMed ID: 11571744
    [Abstract] [Full Text] [Related]

  • 7. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
    Lattanzi JP, Hanlon AL, Hanks GE.
    Int J Radiat Oncol Biol Phys; 1997 Jun 01; 38(3):569-73. PubMed ID: 9231681
    [Abstract] [Full Text] [Related]

  • 8. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy.
    Horwitz EM, Hanlon AL, Pinover WH, Hanks GE.
    Int J Radiat Oncol Biol Phys; 1998 Jun 01; 41(3):519-23. PubMed ID: 9635697
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.
    Anderson PR, Hanlon AL, Horwitz E, Pinover W, Hanks GE.
    Cancer; 2000 Dec 15; 89(12):2565-9. PubMed ID: 11135217
    [Abstract] [Full Text] [Related]

  • 11. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE, Hanlon AL, Epstein B, Horwitz EM.
    Int J Radiat Oncol Biol Phys; 2002 Oct 01; 54(2):427-35. PubMed ID: 12243818
    [Abstract] [Full Text] [Related]

  • 12. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2004 Jan 01; 58(1):19-24. PubMed ID: 14697416
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].
    Geinitz H, Zimmermann F, von Wedel E, Thamm R, Busch R, Feldmann HJ, Molls M.
    Strahlenther Onkol; 2002 Jul 01; 178(7):369-77. PubMed ID: 12163991
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML.
    Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE, Movsas B, Schultheiss TE.
    Int J Radiat Oncol Biol Phys; 1996 Jul 15; 35(5):861-8. PubMed ID: 8751393
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.